Tianjin Redsun Pharmaceutical Co., Ltd. presents its 2026 first quarter report. Key financial figures show a decrease in operating revenue by 18.85% year-on-year, while net profit attributable to shareholders increased by 8.93%. The report details changes in assets and liabilities, shareholder information, and cash flow activities.
Summary generated by AI · Always verify with source document
Tianjin Redsun Pharmaceutical Co., Ltd. 2026 First Quarter Report
The company and all members of the board of directors guarantee the content of the information disclosure is true, accurate, and complete, with no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.